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Botulinum neurotoxin (BoNT), a Category A biothreat agent, is the most potent 
poison known to mankind. Currently no antidote is available to rescue poisoned 
synapses. BoNT acts specifically by blocking neurotransmission primarily at 
peripheral nerve-muscle junctions causing severe flaccid muscle paralysis, which is 
fatal if proper medical care is not provided. The neurotoxin acts by specifically 
entering the presynaptic nerve endings where it interferes with the biochemical 
machinery involved in the process of neurotransmitter release, i.e., neuroexocytosis. 
Most serotypes of BoNT are known to remain active for weeks to months after 
entering the nerves, but BoNT/A is the most potent and long lasting in causing 
muscle paralysis. An effective medical countermeasure strategy requires developing 
a drug that could rescue poisoned neuromuscular synapses, and would include its 
efficient delivery specifically to presynaptic nerve terminals. Here we report 
rescuing of botulinum poisoned nerve cells by Mastoparan-7 (Mas-7), a peptide 
constituent of bee venom, that was delivered through a drug delivery vehicle (DDV) 
constructed from the non-toxic fragment of botulinum neurotoxin itself. We found 
that Mas-7 that was delivered into BoNT/A intoxicated cultured mouse spinal cord 
cells restored over 40% of stimulated neurotransmitter release. The rescue of the 
cell poisoning did not occur from inhibition of the endopeptidase activity of BoNT/A 
against its well known substrate, SNAP-25 that is mechanistically involved in the 
exocytosis process. Rather, Mas-7 induced a physiological host response apparently 
unrelated to SNAP-25, but linked to the phospholipase signal transduction pathway. 
In addition to providing the first effective antidote against botulism, our results 
open new avenues to study the mechanism of exocytosis, and also to examine an 
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alternative cellular mechanism of botulinum neurotoxin action. An effective BoNT-
based DDV can also be utilized for drug delivery against many neuronal and 
neuromuscular disorders. 
 
BoNTs are produced by the anaerobic Clostridium botulinum species of bacteria and are 
the cause of botulism, a life-threatening neuroparalytic disease. They are extremely 
potent food poisons, with a mouse LD50 of 1 ng/kg or less for type A 1, 2. Contamination 
of restaurant, catered or commercial foodstuffs or beverages could cause illness in a large 
number of consumers 1. Aerosol exposure of BoNTs does not occur naturally, but could 
be attempted by bioterrorists to achieve a widespread effect. It has been estimated that a 
single gram of crystalline toxin, evenly dispersed and inhaled, could kill more than one 
million people 2.  
 
BoNTs are large proteins with molecular weight of 150 kDa. They are produced by 
bacteria as a complex, containing the neurotoxin and its associated proteins 3, 4. They are 
synthesized as relatively inactive single chain protoxins and are activated by protease 
nicking to form a dichain molecule (a 50 kDa light chain (LC) and a 100 kDa heavy 
chain (HC)) linked through a disulfide bond5. The HC is responsible for the binding to 
the target nerve cells (through its C-terminus) and translocating the LC into the cell 
cytoplasm (through its N-terminus) 6, 7.  
 
Inside the neuronal cytosol, the LC acts as a Zn2+-endopeptidase against specific 
intracellular protein targets present either on the plasma membrane or on the synaptic 
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vesicle, and inhibits neurotransmitter release by disabling the exocytotic docking/fusion 
machinery 6, 7. BoNTs catalyze proteolysis of specific proteins of the soluble NSF 
attachment protein receptor (SNARE) complex that have been implicated in the 
exocytotic machinery 6, 8. BoNT/A, /C, and /E cleave a 25 kDa synaptosomal associated 
protein (SNAP-25); while synaptobrevin is the target of BoNT/B, /D, /F, /G, and tetanus 
neurotoxin (TeNT) 9-15.  
 
Current therapy for botulism involves respiratory supportive care and the administration 
of antitoxin. The only antitoxins available are equine antitoxin (neutralizing antibodies 
against BoNT/A, /B, and /E, an investigational heptavalent (against ABCDEFG) 
antitoxin BabyBIG®, derived from the blood of human donors vaccinated with a 
pentavalent (ABCDE) toxoid vaccine, is only available for infant botulism 16. An 
antitoxin has to be administered before toxins reach the nerve cells. The therapeutic 
window for using an antitoxin is short. Once the syndrome is developed, the antitoxin is 
less effective since the antitoxin can not get into the nerve cell to neutralize the toxin. The 
flaccid muscle paralysis caused by BoNT/A lasts for several months 17. Therefore 
patients who have already developed the syndrome have to be put under respiratory 
intensive care for this long duration of paralysis 1, 2, 18. The estimated cost for each 
botulism patient under respiratory supportive care could be as high as US $350,000 19. 
This puts a large burden on hospitals, both financially, and in resource management. 
Should a bioterror attack occur, there will be a public health crisis due to the lack of 
effective antidotes against botulism, especially in the absence of reliable presymptomatic 
diagnostics. 
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Mass immunization is not feasible or desirable, primarily because BoNT is an effective 
therapeutic agent against numerous neuromuscular disorders, and also has a wide range 
of cosmetic applications 20.  
 
For relief from BoNT-mediated paralysis, it is important that the poisoned nerve cells are 
rescued through restoration of the neurotransmitter release process. While drugs have 
been designed to block the endopeptidase activity which is believed to be responsible for 
the inhibition of neurotransmitter release, delivery of the drugs specifically to the 
poisoned nerve terminals has remained a major hurdle. 
 
We designed a drug delivery vehicle (DDV) utilizing recombinant BoNT/A heavy chain 
(rHC), which is known to specifically bind to the presynaptic nerve terminals and be 
internalized via endocytosis. The DDV construct was a modification of that developed by 
Goodnough et al.21 consisting of a targeting molecule, Cy3 labeled rHC, linked by a 
disulfide bond to a drug stimulant, Oregon green 488 (OG488) labeled 10 kDa dextran. 
We attached Mas-7 with the DDV (DDV-Mas-7) (See supplementary figure S1 for 
details on DDV and DDV-Mas-7 structures) and tested its efficacy in rescuing cultured 
mouse spinal cord neuronal cells poisoned with BoNT/A (Fig. 1). Mas-7 is a wasp venom 
derived peptide known to be a phospholipase A2 (PLA2) activator, which effectively 
stimulated acetylcholine exocytosis in PC12 cells in a SNAP-25 independent manner 22. 
[3H]glycine release assay was used to assess the recovery from BoNT/A poisoning.  The 
experimental design was to mimic a therapeutic application of the DDV strategy to treat 
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individuals poisoned with BoNT/A and exhibiting clinical symptoms of botulism.   
Three-week old mouse spinal cord neuronal cultures were treated with 1 pM BoNT/A at 
37oC for 8 hours. After washing to remove excess toxin, cells were treated with DDV-
Mas-7 at a concentration of 100 nM for 16 hours at 37oC. Vesicular neurotransmitter 
release, measured by the 80 mM K+-evoked [3H]glycine release assay, was substantially 
restored (~40%; Fig. 1A).   
 
Interestingly, there was only a partial cleavage of SNAP-25 (28% of total SNAP-25 
protein) in neurons treated with 1 pM BoNT/A, a concentration that almost completely 
blocked the [3H]glycine release due to 80 mM K+ stimulation (Fig. 1B). This suggested 
that SNAP-25 cleavage may not be the only factor responsible for the inhibition of 
neurotransmitter release due to BoNT/A. Keller and Neale also reported that a dose-
response data with BoNT/A produced non-overlapping curves for SNAP-25 proteolysis 
and blockade of neurotransmitter release 23. It is noteworthy that in BoNT/A poisoned 
neurons, DDV-Mas-7 treatment had no effect on SNAP-25 cleavage, suggesting that 
Mas-7 in DDV was effective in rescuing neurons from BoNT/A toxicity via a pathway 
independent of SNAP-25.  To our knowledge, this is the first experimental demonstration 
of a prospective therapeutic approach to treat botulism in a relevant peripheral neuronal 
model combined with a feasible targeted drug delivery technology.  
 
For BoNT/A, the widely accepted molecular explanation of its mechanism of action is 
that toxicity is due to its zinc-dependent endopeptidase activity via proteolysis of SNAP-
25, an essential component of the exocytotic SNARE complex.  An alternative 
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mechanism, although not mutually exclusive, is that the BoNT/A affects phospholipase 
A2 (PLA2) 22, 24-25 and Rho-GTPase (RhoB) 26 in stimulus-induced neurotransmitter 
release.  According to this mechanism, stimulus-induced increase in intraterminal free 
Ca2+ concentration ([Ca2+]i) activates PLA2, which causes arachidonic acid (AA) release 
from membrane phospholipids.  AA has been proposed to act as a fusogen in the vesicle 
fusion process.  Lysophosphatidic acid (LPA), the other product of PLA2 action, acts via 
LPA receptors to stimulate Rho-GTPase (Rho-B), which regulates actin cytoskeletal 
organization.  Actin disorganization has been proposed to be a prerequisite for 
intraterminal vesicle migration and exocytosis.  Our results have shown that BoNT/A 
inhibits neuroexocytosis by interfering with both PLA2-mediated AA release in PC12 
cells 22, 24-25 and RhoB-mediated actin disorganization26. Our observation of Mas-7 based 
rescue of BoNT/A-poisoned neuronal cells is likely to engage this pathway of 
neurotransmitter release. 
 
A series of control and background experiments were carried out to ensure understanding 
and utility of DDV-Mas-7 as a viable therapeutic approach against botulism. First, we 
observed that in 3-week old cultured mouse embryonic spinal cord neurons poisoned with 
1 pM BoNT/A, Mas-7 alone or Mas-7 plus high (80 mM) K+ was able to induce 
neurotransmitter ([3H]glycine) release; high K+ alone was ineffective (data not shown). 
Second, since the targeted DDV approach is based on the premise of a selective entry of 
DDV into presynaptic nerve terminals via BoNT/A receptor mediated endocytosis, we 
demonstrated by competition experiments that the uptake of the DDV-Mas-7 was via 
BoNT/A receptors.  In these experiments (Fig. 2), 3-week old spinal cord cultures were 
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exposed for 16 hours to DDV (200 nM) alone or to DDV plus a 1-, 3-, or 10-fold excess 
of unlabeled rHC or BoNT/A holotoxin added to cultures simultaneously.  As seen in Fig. 
2, in the absence of rHC or BoNT/A, DDV uptake and dextran separation were as 
expected; however, a 10-fold excess of rHC or BoNT/A holotoxin totally blocked the 
uptake of DDV.  These results suggested that DDV entry into neurons occurred by the 
same route as that used by BoNT/A. Third, we considered the possibility that in neurons, 
the processes of exocytosis and endocytosis might be tightly coupled, i.e., interruption of 
exocytosis, as in BoNT/A poisoning, might halt endocytosis as well.  To discount this 
possibility, we demonstrated uptake of labeled DDV-Mas-7 (Cy3 labeled rHC, red 
fluorescence) in spinal cord neurons previously exposed to a high concentration (1 nM) 
of Alexa 488-labeled BoNT/A (green florescence) which had completely blocked K+-
stimulated [3H]glycine release.   To examine DDV-Mas-7 uptake in these cells, the cells 
were washed once using warm culture medium and reincubated at 37oC with 100 nM 
DDV-Mas-7 for 16 hours. Confocal microscopy results indicated that both BoNT/A and 
DDV-Mas-7 were taken up in the same cell pool, but localized in separate population of 
endosomes (Fig. 3), demonstrating internalization of DDV-mas-7 via endocytosis into 
BoNT/A poisoned neurons. Neale et al. also reported that BoNT/A blocked synaptic 
vesicle exocytosis, but not endocytosis at nerve terminal 27. It is suggested that the 
exocytosis and endocytosis are not tightly coupled in BoNT/A poisoned neurons. 
  
Therapeutic targeting is important for two main reasons: (a) delivering an effective high 
concentration of the therapeutic compound to the site of toxicity, e.g., nerve terminals for 
botulism, and (b) minimizing systemic toxicity, if any, due to treatment compounds. To 
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demonstrate the feasibility of delivering a therapeutic compound via the DDV, we 
examined the separation of the prototype drug carrier OG488-dextran from DDV. Spinal 
cord neurons were treated with 200 nM labeled DDV for 16 hours at 37oC. Confocal 
microscopic images were analyzed by utilizing the Bio-Rad AutoDeblur and 
AutoVisualize software (see supplementary information Fig. S2 for detail). The results 
indicated that about 40% of the drug carrier components were separated from DDV and 
diffused into cytosol from endosome in 3 week-old cultures (Fig. 4). Results also 
revealed that both the separation of the drug carrier from DDV and the neuronal function 
of glycine release was cell maturation dependent (supplementary information Fig. S2, 
table ST1). To test the toxicity of rHC in our experimental model, we compared the 
inhibition of 80 mM K+ stimulated [3H]glycine release due to increasing concentrations 
of rHC or native BoNT/A holotoxin by the assay described in Methods (supplementary 
information).  Results obtained with a given batch of toxin (Figure S3) showed that 
BoNT/A was effective as expected with an IC50 of <1 pM and a total inhibition at ~0.1 
nM. However, the rHC was relatively nontoxic at 10 nM or higher (supplementary 
information Fig. S3).   
 
In conclusion, this report provides new knowledge of endocytosis and exocytosis as well 
as of BoNT trafficking and action.  In particular, the results showing the efficacy of 
DDV-Mas-7 in rescuing neurons from botulism is consistent with our previous reports on 
a PLA2- and RhoB-mediated mechanism of BoNT/A toxicity. In addition, these results 
suggest an alternative approach towards botulism intervention other than the one 
commonly emphasized, i.e., protection of vesicle fusion proteins, e.g., SNAP-25 for 
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BoNT/A.  Notably, application of this DDV approach to antagonize botulism is not 
necessarily limited to the neuronal targeting of a PLA2 activator as shown here, but also 
should be useful for delivery of other prospective antidotes such as protease inhibitors to 
protect the vesicle fusion proteins as applicable.  Finally, the success in the DDV strategy 
against botulism shown here may open new avenues in developing technologies to treat 
other neurological disorders that require a targeted delivery of therapeutics to affected 
neurons or tissues.      
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METHODS SUMMARY 
See Supplementary Information for detailed methods. 
3[H]glycine release assay. 3[H]glycine release was determined by a modification of the 
method described by Williamson et al.28 Spinal cord cells were incubated at 37oC for 30 
min in HEPES-buffered saline (HBS) containing 2 mCi/ml 3[H]glycine. The cells were 
washed briefly with Ca2+-free HBS and incubated sequentially for 7 min in each of the 
following modified HBS solutions: 5 mM KCl/0 mM Ca2+, 80 mM KCl/2 mM Ca2+ and 5 
mM KCl/0 mM Ca2+. Each incubation solution was collected, and the radioactivity was 
determined by scintillation counting.  
 
Fluorescent images. Uptake of DDV by spinal cord neurons, release of dextran from 
DDV and rHC localization were determined by confocal microscopy. Cells were exposed 
to DDV, Cy3-labeled rHC, or OG488-labeled dextran in growth medium for 16 h at a 
concentration of 200 nM at 37oC. Cells were subsequently washed and fixed overnight 
with 2% paraformaldehyde. The anti-endosome antibody was then used to determine rHC 
localization. The coverslips containing fixed cells were mounted between a glass slide 
and glass coverslip and fluorescent images were viewed on a Bio-Rad 2000 laser 
confocal microscope.  
 
SNAP-25 Immunoblotting. Immunoblotting was performed using an anti-SNAP-25 
antibody. After electrophoresis in 4-12% gradient polyacrylamide gels, the proteins were 
transferred to polyvinylidene difluoride (PVDF) membrane. The anti-SNAP-25 antibody 
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was used to determine the full-length and truncated SNAP-25 protein. Scanned images of 
Western blots were produced and analyzed utilizing Bio-Rad quantity-one software. 
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FIG LEGENDS 
 
Fig.1. Restoration of stimulated [3H]glycine release function in BoNT/A poisoned 
neurons by treatment with DDV-Mas-7.  
A. Potassium (80 mM)-evoked glycine release was measured in 3 week-old mouse 
spinal cord neuronal cultures. B. Western blots showing cleavage of SNAP-25 due to 1 
pM BoNT/A. Spinal cord cells were solubilized in sample buffer and 5 mg of total 
cellular protein was used for Western blotting with SNAP-25 antibody (SMI-81, 
Sternberger Monoclonals, Inc. Lutherville, MD). SNAP-25 cleavage was determined by 
densitometric analyses of Western blots. SNAP-25, a full-length 25 KDa SNAP-25 
protein; SNAP-25A, a truncated from of SNAP-25 protein cleaved with a 9 c-terminal 
residues by BoNT/A.  (1) control spinal cord cultures not exposed to BoNT/A, (2) Spinal 
cord cultures incubated with 1 pM toxin for 8 h at 37°C, (3) spinal cord cultures 
incubated with 1 pM toxin for 8 h at 37°C washed to remove toxin, and then incubated 
with 100 nM of toxin-free DDV-Mas-7 for 16 h at 37°C,  
 
Fig.2. Fluorescently labeled DDV uptake in neurons is via BoNT/A receptors. 
Fluorescent images of mouse spinal cord neurons demonstrated that both unlabeled 
BoNT/A holotoxin and rHC compete with fluorescent DDV molecules for entry into 
cells. The DDV consisted of Cy3 (red fluorescence) labeled rHC conjugated to OG488 
(green fluorescence) labeled 10 kDa dextran. Images in upper panel were obtained from 
cultures exposed for 16 h under the following conditions: (A1) DDV (200 nM in all 
experiments) in the absence of rHC; (B1) DDV and rHC (200 nM); (C1) DDV and rHC 
(600 nM); and (D1) DDV and rHC (2 mM). Images in lower panel were obtained from 
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cultures exposed for 16 h under the following conditions: (A2) DDV in the absence of 
BoNT/A; (B2) DDV and BoNT/A (200 nM); (C2) DDV and BoNT/A (600 nM); and 
(D2) DDV and BoNT/A (2 mM). DDV and rHC or BoNT/A were added simultaneously. 
Fluorescent images were analyzed by Bio-Rad 2000 laser confocol microscope. Alexa 
488 was excited at 488 nm line of an argon laser and detected with a 530-nm cutoff filter; 
Cy3 was excited at 543 nm line of an argon laser and detected with a 565-nm cutoff filter. 
 
Fig.3. Exocytosis and endocytosis are not tightly coupled in BoNT/A poisoned 
neurons.  
BoNT/A was labeled with Alexa 488 (green fluorescence). Three week-old cultured 
mouse spinal cord neurons were incubated with a culture medium containing 1 nM of 
Alexa 488-BoNT/A for 8 hours at 37oC. Excess Alexa 488-BoNT/A was removed by 
washings 3 times with fresh culture medium. The cells were incubated with fresh medium 
for 1 hour and then incubated in medium containing 100 nM Cy3 (red fluorescence) 
labeled DDV-Mas-7 (Fig. S1B) for 16 hours. Fluorescent images were analyzed by Bio-
Rad 2000 laser confocol microscope. Alexa 488 was excited at 488 nm line of an argon 
laser and detected with a 530-nm cutoff filter; Cy3 was excited at 543 nm line of an 
argon laser and detected with a 565-nm cutoff filter. 
 
Fig.4. The drug carrier molecule in DDV separates and translocates into neuronal 
cytosol. 
Three-week old spinal cord cultures were incubated for 16 h with 200 nM solutions of 
fluorescently labeled DDV and then labeled with anti-endosome antibody as described 
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under methods. Confocal images shown are as follows: A, red-rHC: fluorescence elicited 
at an excitation wavelength of 543 nm; B, green-OG488-dextran: fluorescence elicited at 
an excitation wavelength of 488 nm; C, bright blue-Alexa 633-endosomes: fluorescence 
elicited at an excitation wavelength of 632 nm; D, overlay of red and green showing 
either co-localization (orange) or separation of rHC and dextran; E, overlay of red and 
blue showing either the localization (magenta) of rHC in the endosomes as believed or its 
release into the cytosol; F, overlay of green and blue showing either localization (light 
blue or greenish blue) of dextran in the endosomes or its release into the cytosol. 
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